Take a look through some of the notable data presentations at this year's ESMO Congress.
Feature|Articles|June 30, 2026
5 urologic oncology headlines you missed in Q2 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A roundup of the key stories across genitourinary cancers from the second quarter of 2026.
Advertisement
Advertisement
The second quarter of 2026 brought several practice-changing developments across genitourinary oncology, from new FDA approvals to pivotal phase 3 data presented at major scientific meetings. Advances in bladder, prostate, and kidney cancer expanded treatment options in both the adjuvant and perioperative settings while highlighting the growing role of biomarker-guided care and combination strategies.
Related to this article
Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
In TALAPRO-3, talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide (HR, 0.48; P < .0001) in HRR-mutated mAPMN/S prostate cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Advertisement
Advertisement